RecruitingPHASE1, PHASE2NCT06620302
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Studying Fibrolamellar hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Michael V OrtizPediatric Early Phase Clinical Trial Network
- Intervention
- Bcl-XL Proteolysis Targeting Chimera DT2216(biological)
- Enrollment
- 81 enrolled
- Eligibility
- 1-39 years · All sexes
- Timeline
- 2025 – 2031
Study locations (20)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06620302 on ClinicalTrials.govOther trials for Fibrolamellar hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06789198Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACAUniversity Hospital Tuebingen
- RECRUITINGPHASE1, PHASE2NCT06027086DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGPHASE1NCT05937295FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint InhibitionUniversity Hospital Tuebingen
- RECRUITINGPHASE1, PHASE2NCT05468359Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT04380545Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT04134559Checkpoint Inhibition In Pediatric Hepatocellular CarcinomaAllison O'Neill, MD